Literature DB >> 31932381

Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens.

M Biagi1, A Shajee1, A Vialichka2, M Jurkovic2, X Tan2, E Wenzler3.   

Abstract

The Serratia marcescens enzyme (SME) is a chromosomally encoded carbapenemase with no known optimal treatment. Various β-lactam/β-lactamase inhibitors and comparators were evaluated against 8 SME producers via broth microdilution. Four isolates were subsequently tested via time-kill analyses. All isolates were resistant to imipenem, imipenem-relebactam, and meropenem but susceptible to ceftazidime, ceftazidime-avibactam, and meropenem-vaborbactam. Ceftazidime, imipenem-relebactam, and meropenem-vaborbactam were bactericidal against 3, 0, and 4 isolates, respectively. Meropenem-vaborbactam may be a potential option for severe SME-producing infections.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  SME; Serratia marcescens; carbapenem-resistant Enterobacteriaceae; imipenem-relebactam; meropenem-vaborbactam

Mesh：

Substances：

Year:  2020        PMID： 31932381      PMCID： PMC7179323          DOI： 10.1128/AAC.02255-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Occurrence of an SME-2-producing Serratia marcescens isolate in Canada.

Authors:  Amélie Carrër; Laurent Poirel; Johann D Pitout; Deirdre Church; Patrice Nordmann
Journal:  Int J Antimicrob Agents       Date:  2007-12-20       Impact factor: 5.283

2.  Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates.

Authors:  Y J Yang; P J Wu; D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

3.  Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®.

Authors:  Timothy A Blizzard; Helen Chen; Seongkon Kim; Jane Wu; Rena Bodner; Candido Gude; Jason Imbriglio; Katherine Young; Young-Whan Park; Aimie Ogawa; Susan Raghoobar; Nichelle Hairston; Ronald E Painter; Doug Wisniewski; Giovanna Scapin; Paula Fitzgerald; Nandini Sharma; Jun Lu; Sookhee Ha; Jeff Hermes; Milton L Hammond
Journal:  Bioorg Med Chem Lett       Date:  2014-01-03       Impact factor: 2.823

4.  Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens.

Authors:  M Biagi; A Shajee; A Vialichka; M Jurkovic; X Tan; E Wenzler
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

5.  In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.

Authors:  T Wu; K Meyer; A T Harrington; L H Danziger; E Wenzler
Journal:  J Antimicrob Chemother       Date:  2019-05-01       Impact factor: 5.790

6.  SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains.

Authors:  A M Queenan; C Torres-Viera; H S Gold; Y Carmeli; G M Eliopoulos; R C Moellering; J P Quinn; J Hindler; A A Medeiros; K Bush
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

7.  Sensitive screening tests for suspected class A carbapenemase production in species of Enterobacteriaceae.

Authors:  Fernando Pasteran; Tania Mendez; Leonor Guerriero; Melina Rapoport; Alejandra Corso
Journal:  J Clin Microbiol       Date:  2009-04-22       Impact factor: 5.948

8.  Identification of acquired antimicrobial resistance genes.

Authors:  Ea Zankari; Henrik Hasman; Salvatore Cosentino; Martin Vestergaard; Simon Rasmussen; Ole Lund; Frank M Aarestrup; Mette Voldby Larsen
Journal:  J Antimicrob Chemother       Date:  2012-07-10       Impact factor: 5.790

9.  PGAdb-builder: A web service tool for creating pan-genome allele database for molecular fine typing.

Authors:  Yen-Yi Liu; Chien-Shun Chiou; Chih-Chieh Chen
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

10.  Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants.

Authors:  Elizabeth G Rhee; Matthew L Rizk; Nicole Calder; Marcela Nefliu; Steven J Warrington; Michael S Schwartz; Eric Mangin; Keith Boundy; Pratik Bhagunde; Francheska Colon-Gonzalez; Patricia Jumes; Yang Liu; Joan R Butterton
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191
View more
  6 in total

1.  Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens.

Authors:  M Biagi; A Shajee; A Vialichka; M Jurkovic; X Tan; E Wenzler
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 2.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

Review 3.  New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.

Authors:  J Nicholas O'Donnell; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2022-06-21       Impact factor: 5.938

Review 4.  Genetic Diversity, Biochemical Properties, and Detection Methods of Minor Carbapenemases in Enterobacterales.

Authors:  Rémy A Bonnin; Agnès B Jousset; Cécile Emeraud; Saoussen Oueslati; Laurent Dortet; Thierry Naas
Journal:  Front Med (Lausanne)       Date:  2021-01-20

Review 5.  A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date.

Authors:  Toni A Campanella; Jason C Gallagher
Journal:  Infect Drug Resist       Date:  2020-11-25       Impact factor: 4.003

6.  Mutations responsible for the carbapenemase activity of SME-1.

Authors:  Vidhu Agarwal; Akhilesh Tiwari; Pritish Varadwaj
Journal:  RSC Adv       Date:  2022-08-15       Impact factor: 4.036
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.